DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06603571

Active not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Management With LY3841136 and Tirzepatide, Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Assets

Eloralintide / Tirzepatide

Listed sites

52

Recruiting sites

—

Enrollment

350

estimated

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI ≥27•HbA1c ≥7%

Primary endpoint

•Body weight, % change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06603571
Org study ID18809
Secondary IDW8M-MC-CWMM Master ProtocolEli Lilly and Company
Secondary IDW8M-MC-LAA2Eli Lilly and Company

Timeline

Milestones

Study first posted2024-09-19actual
Study start2024-09-20actual
Last update posted2025-09-26actual
Primary completion2026-06estimated (month precision)
Study completion2026-08estimated (month precision)

Assets

Investigational agents

EloralintideTirzepatide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
Maximum age75 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

W8M-MC-LAA2

•Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²)
•Have Type 2 Diabetes
•Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening

W8M-MC-CWMM:

•Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)

Exclusion criteria

W8M-MC-LAA2

•Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
•Have an on-going or history of bradyarrhythmia and/or sinus bradycardia
•Have an elevated resting pulse rate (mean >100 beats per minute (bpm)) or reduced resting pulse rate (mean <60 bpm) at screening
•Have any of the following cardiovascular conditions within 6 months prior to screening:
–acute myocardial infarction
–cerebrovascular accident (stroke)
–unstable angina, or
–hospitalization due to congestive heart failure
•Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45 milliliters per minute (mL/min)/1.73 m2
•Have a history of acute or chronic pancreatitis
•Have fasting triglycerides >500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening
•All concomitant medications should be at a stable dose for at least 3 months prior to screening

W8M-MC-CWMM

•Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
•Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
•Have poorly controlled hypertension.
•Have a history of symptomatic gallbladder disease within the past 2 years
•Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
•Have a lifetime history of suicide attempts.

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
4
Safety / tolerability / PK
2
Glycemic / diabetes
1

Weight & body composition

4 endpoints
Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 48

Body weight, % change

percent change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline in Body Weight

Time frame:Baseline, Week 48

Body weight, absolute change (kg)

change from baseline, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥5% Body Weight Reduction

Time frame:Week 48

≥5% weight-loss responders

threshold achievement, improvement

Secondary/protocol endpoint

Percentage of Participants Who Achieve ≥10% Body Weight Reduction

Time frame:Week 48

≥10% weight-loss responders

threshold achievement, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Change from baseline in Hemoglobin A1c (HbA1c)

Time frame:Baseline, Week 48

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Safety / tolerability / PK

2 endpoints
Secondary/protocol endpoint

Pharmacokinetics (PK): Area Under the Curve (AUC) of LY3841136

Time frame:Baseline, Week 48

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

PK: Maximum Concentration (Cmax) of LY3841136

Time frame:Baseline, Week 48

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.